Day/night rhythm of hemostatic factors in obstructive sleep apnea

Sleep

Volumn 33, Issue 3, 2010, Pages 371-377

  Von Känel, Roland ^a,b   Natarajan, Loki ^c   Ancoli Israel, Sonia ^b   Mills, Paul J ^b   Loredo, José S ^d   Dimsdale, Joel E ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Blood coagulation; Cardiovascular disease; Day night rhythm; Fibrinolysis; Obstructive sleep apnea

Indexed keywords

D DIMER; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGE DISTRIBUTION; APNEA; ARTICLE; BODY MASS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPNEA; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPOPNEA; MALE; MEAN ARTERIAL PRESSURE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; SEX DIFFERENCE; SLEEP APNEA SYNDROME; SMOKING; THROMBOSIS;

EID: 77649239539     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/33.3.371     Document Type: Article

References (49)

1. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol 2008;52:686-717.
2. Sorajja D, Gami AS, Somers VK, Behrenbeck TR, Garcia-Touchard A, Lopez-Jimenez F. Independent association between obstructive sleep apnea and subclinical coronary artery disease. Chest 2008;133:927-33.
3. Hung J, Whitford eg, parsons RW, Hillman DR. Association of sleep apnoea with myocardial infarction in men. Lancet 1990;336:261-4.
4. Peker Y, Hedner J, Kraiczi H, Löth S. Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. Am J Respir Crit Care Med 2000;162:81-6.
5. Mooe T, Franklin KA, Holmström K, Rabben T, Wiklund U. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med 2001;164:1910-3.
6. von Känel R, Dimsdale JE. Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 2003;124:1956-67.
7. Steiner S, Jax T, Evers S, Hennersdorf M, Schwalen A, Strauer BE. Altered blood rheology in obstructive sleep apnea as a mediator of cardiovascular risk. Cardiology 2005;104:92-6.
8. Wessendorf TE, Thilmann AF Wang YM, Schreiber A, Konietzko N, Teschler H. Fibrinogen levels and obstructive sleep apnea in ischemic stroke. Am J Respir Crit Care Med 2000;162:2039-42.
9. Nobili L, Schiavi G, Bozano E, De Carli F, Ferrillo F, Nobili F. Morning increase of whole blood viscosity in obstructive sleep apnea syndrome. Clin Hemorheol Microcirc 2000;22:21-7.
10. Reinhart WH, Oswald J, Walter R, Kuhn M. Blood viscosity and platelet function in patients with obstructive sleep apnea syndrome treated with nasal continuous positive airway pressure. Clin Hemorheol Microcirc 2002;27:201-7.
11. Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 2004;59:777-82.
12. Shimizu M, Kamio K, Haida M, et al. Platelet activation in patients with obstructive sleep apnea syndrome and effects of nasal-continuous positive airway pressure. Tokai J Exp Clin Med 2002;27:107-12.
13. Geiser T, Buck F, Meyer BJ, Bassetti C, Haeberli A, Gugger M. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. rRespiration 2002;69:229-34.
14. Hui DS, Ko FW, Fok JP, et al. The effects of nasal continuous positive airway pressure on platelet activation in obstructive sleep apnea syndrome. Chest 2004;125:1768-75.
15. Rangemark, C, Hedner, JA, Carlson, JT, et al Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 1995;18:188-94.
16. von Känel R, Loredo JS, Ancoli-Israel S, Mills PJ, Dimsdale JE. Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples. Metabolism 2007;56:969-76.
17. Zamarrón C, Ricoy J, Riveiro A, Gude F. Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension. Lung 2008;186:151-6.
18. Ishikawa J, Hoshide S, Eguchi K, et al. Increased low-grade inflammation and plasminogen-activator inhibitor-1 level in nondippers with sleep apnea syndrome. J Hypertens 2008;26:1181-7.
19. Vaughan DE. Pai-1 and atherothrombosis. J Thromb Haemost 2005;3:1879-83.
20. Haus E. Chronobiology of hemostasis and inferences for the chronotherapy of coagulation disorders and thrombosis prevention. Adv Drug Deliv Rev 2007;59:966-84.
21. Chasen E, Muller JE. Cardiovascular triggers and morning events. Blood Press Monit 1998;3:35-42.
22. Kuniyoshi FH, Garcia-Touchard A, Gami AS, et al. Day-night variation of acute myocardial infarction in obstructive sleep apnea. J Am Coll Cardiol 2008;52:343-6.
23. Hanly P, Sasson Z, Zuberi N, Lunn K. ST-segment depression during sleep in obstructive sleep apnea. Am J Cardiol 1993;71:1341-5.
24. Seljeflot I, Eritsland J, Andersen P, Arnesen H. Global fibrinolytic capacity assessed by the serum D-dimer test. correlation between basal and stimulated values. Thromb Res 1994;75:157-62.
25. Rudnicka AR, Rumley A, Lowe GD, Strachan DP. Diurnal, seasonal, and blood processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation 2007;115:996-1003.
26. Maccallum PK, Cooper JA, Martin J, Howarth DJ, Meade TW, Miller GJ. Haemostatic and lipid determinants of prothrombin fragment F1.2 and D-dimer in plasma. Thromb Haemost 2000;83:421-6.
27. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques, and scoring system for sleep stages of human subjects. NIH, Washington, DC: US Government Printing Office: Publication No. 204, 1968.
28. Marler MR, Gehrman P, Martin JL, Ancoli-Israel S. The sigmoidally transformed cosine curve: the sigmoidally transformed cosine curve: a mathematical model for circadian rhythms with symmetric non-sinusoidal shapes. Stat Med 2006;25:3893-904.
29. Tong YL. Parameter estimation in studying circadian rhythms. Biometrics 1976;32:85- 94.
30. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data, Oxford Science Publication, 1994.
31. Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med 2004;66:411-21.
32. Cohen J. Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Earlbaum Associates: 1988.
33. bastelica d, morange p, berthet b, et al. stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002;22:173-8.
34. Alessi MC, Juhan-Vague I. Pai-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006;26:2200-7.
35. Grundy SM, Brewer HB JR, Cleeman JI, Smith SC JR, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Defi-nition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
36. Lam JC, Ip MS. An update on obstructive sleep apnea and the metabolic syndrome. curr Opin Pulm Med 2007;13:484-9.
37. Lowe GD. Fibrin D-dimer and cardiovascular risk. semin Vasc Med 2005;5:387-98.
38. Danesh J, Whincup P0, Walker M, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001;103:2323-7.
39. Fassbender K, Dempfle CE, Mielke O, et al. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke 1999;30:2101-4.
40. Lip GY. Lowe GD. Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci (Lond) 1995;89:205-14.
41. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration 4of cross linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994;90:2236-40.
42. van der Bom JG, Bots ML, Haverkate F, Meyer P, Hofman A, Grobbee DE, Kluft C. Fibrinolytic activity in peripheral atherosclerosis in the elderly. Thromb Haemost 1999;81:275-80.
43. Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001;86:366-73.
44. Selwyn AP. Prothrombotic and antithrombotic pathways in acute coronary syndromes. Am J Cardiol 2003;91:3H-11H.
45. Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002;106:491-6.
46. McNicholas WT. Cardiovascular outcomes of CPAP therapy in obstructive sleep apnea syndrome. Am J P1hysiol Regul Integr Comp Physiol 2007;293:R1666-70.
47. von Känel, R, Loredo, JS, Ancoli-Israel, S, Dimsdale JE. Association between sleep apnea severity and blood coagulability: treatment effects of nasal continuous positive airway pressure. Sleep Breath 2006;10,139-46.
48. Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int 1991;8:336-51.
49. Thögersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-7.